Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
52 Week high
52 Week low
GlobeNewsWire • 2 days ago • RPRXRoyalty Pharma Appoints Eric Schneider as Chief Technology Officer
Seeking Alpha • 17 days ago • RPRXRoyalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone
GlobeNewsWire • 18 days ago • RPRXRoyalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
GlobeNewsWire • 18 days ago • RPRXRoyalty Pharma to Present at Upcoming Investor Conferences
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.